沙眼治疗市场规模、份额、成长分析(按治疗、按药物类别、按给药途径、按年龄、按分销管道、按地区)- 行业预测,2025 年至 2032 年
市场调查报告书
商品编码
1770771

沙眼治疗市场规模、份额、成长分析(按治疗、按药物类别、按给药途径、按年龄、按分销管道、按地区)- 行业预测,2025 年至 2032 年

Trachoma Treatment Market Size, Share, and Growth Analysis, By Treatment (Medication, Surgery), By Drug Class (Macrolides, Tetracycline), By Route of Administration, By Age-group, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 188 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2023 年全球沙眼治疗市场规模为 5.302 亿美元,预计将从 2024 年的 5.6784 亿美元增长到 2032 年的 9.8298 亿美元,预测期内(2025-2032 年)的复合年增长率为 7.1%。

沙眼治疗市场经历了显着成长,这主要得益于新兴地区(主要是非洲、亚洲和拉丁美洲)的高发病率。政府措施和国际资金的增加,透过大规模药物管理和公共卫生宣传活动加速了沙眼的根除工作。阿奇霉素等抗生素的可近性得到改善(通常透过捐赠项目提供),进一步提高了治疗效果。此外,提高意识和卫生教育工作在预防和降低再感染率方面发挥关键作用。然而,医疗基础设施不足、卫生条件差、依赖捐助援助以及某些人群的认知度低等挑战,阻碍了偏远地区及时治疗和持续的疾病控制活动。解决这些问题对于持续的市场扩张至关重要。

目录

介绍

  • 调查目的
  • 研究范围
  • 定义

调查方法

  • 资讯采购
  • 二次资料和一次资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分机会分析

市场动态与展望

  • 市场概览
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 市场吸引力指数(2024年)
  • PESTEL分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 技术分析
  • 案例研究
  • 监管分析

沙眼治疗市场规模(依治疗方法和复合年增长率) (2025-2032)

  • 市场概览
  • 药品
  • 外科手术
  • 其他的

沙眼治疗市场规模(按药物类别和复合年增长率) (2025-2032)

  • 市场概览
  • 大环内酯类
  • 四环霉素
  • 眼科抗感染药物
  • 磺胺类药物

沙眼治疗市场规模(依给药途径和复合年增长率) (2025-2032)

  • 市场概览
  • 口服
  • 外用

沙眼治疗市场规模(按年龄和复合年增长率) (2025-2032)

  • 市场概览
  • 孩子
  • 成人
  • 老年人

沙眼治疗市场规模(按分销管道和复合年增长率) (2025-2032)

  • 市场概览
  • 医院药房
  • 零售药局
  • 网路药局

沙眼治疗市场规模(按地区)及复合年增长率(2025-2032)

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业市场定位(2024年)
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市场占有率分析(2024年)
  • 主要企业简介
    • 公司详情
    • 产品系列分析
    • 公司分部份额分析
    • 收益同比对比(2022-2024 年)

主要企业简介

  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Mylan NV(US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi(France)
  • Pfizer Inc.(US)
  • GlaxoSmithKline plc(UK)
  • Novartis AG(Switzerland)
  • Bayer AG(Germany)
  • Eli Lilly and Company(US)
  • Merck & Co., Inc.(US)
  • Allergan(Ireland)
  • AstraZeneca(UK)
  • AbbVie Inc.(US)
  • Johnson & Johnson Private Limited(US)
  • Cipla Inc.(US)
  • Bausch Health Companies Inc.(Canada)
  • Abbott(US)
  • Fresenius Kabi AG(Germany)

结论和建议

简介目录
Product Code: SQMIG35I2407

Global Trachoma Treatment Market size was valued at USD 530.2 million in 2023 and is poised to grow from USD 567.84 million in 2024 to USD 982.98 million by 2032, growing at a CAGR of 7.1% during the forecast period (2025-2032).

The trachoma treatment market is experiencing significant growth, driven by the high prevalence of the disease in developing regions, especially Africa, Asia, and Latin America. Increased government initiatives and international funding have accelerated eradication efforts through mass medication and public health campaigns. Improved access to antibiotics like azithromycin, often provided through donation programs, further supports treatment availability. Moreover, rising awareness and hygiene education initiatives play a vital role in prevention and reducing reinfection rates. However, challenges such as inadequate healthcare infrastructure, poor sanitation, reliance on donor aid, and low awareness in certain populations hinder timely treatment and ongoing disease control efforts in remote areas. Addressing these issues is crucial for sustained market advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Trachoma Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Trachoma Treatment Market Segments Analysis

Global Trachoma Treatment Market is segmented by Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel and region. Based on Treatment, the market is segmented into Medication, Surgery and Others. Based on Drug Class, the market is segmented into Macrolides, Tetracycline, Ophthalmic anti-infective and Sulfonamides. Based on Route of Administration, the market is segmented into Oral and Topical. Based on Age-group, the market is segmented into Children, Adults and Geriatric. Based on Distribution Channel, the market is segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Trachoma Treatment Market

The Global Trachoma Treatment market is significantly driven by the high prevalence of trachoma in many developing countries, especially in certain areas of Africa and Asia. Factors such as overcrowded living conditions, poor sanitation, and limited access to clean water exacerbate the issue, leading to a continual need for effective treatment options. This ongoing health challenge necessitates the implementation of extensive intervention programs, which in turn amplifies the demand for trachoma treatment products across these regions. As a result, the intersection of these elements plays a crucial role in propelling the growth and penetration of the treatment market globally.

Restraints in the Global Trachoma Treatment Market

The global trachoma treatment market faces significant constraints due to the inadequate healthcare infrastructure prevalent in many trachoma-endemic regions. This poor infrastructure hampers crucial aspects like diagnosis, treatment implementation, and patient follow-up. A lack of trained healthcare personnel, substandard medical facilities, and ineffective logistical systems greatly hinder the execution of mass treatment initiatives. Such barriers delay the delivery of interventions, reduce the coverage of treatment efforts, and diminish the effectiveness of public health campaigns aimed at eradicating the disease. Consequently, these factors collectively restrain the overall growth and development of the trachoma treatment market on a global scale.

Market Trends of the Global Trachoma Treatment Market

The Global Trachoma Treatment market is witnessing a transformative trend driven by AI-driven mobile diagnostics, which promise to redefine early detection and screening practices. These innovative, technology-enhanced applications are pivotal in suburban and under-resourced areas, streamlining the process of diagnosing trachoma while reducing dependency on specialized ophthalmic professionals. Consequently, this advancement enables extensive population screenings, enhancing both treatment accuracy and accessibility. As a result, healthcare systems can leverage real-time data analytics for improved surveillance models and informed decision-making, ultimately leading to more effective and efficient management of trachoma on a global scale. This trend signals significant growth potential in the market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Analysis
  • Case Studies
  • Regulatory Analysis

Global Trachoma Treatment Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Medication
  • Surgery
  • Others

Global Trachoma Treatment Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • Macrolides
  • Tetracycline
  • Ophthalmic anti-infective
  • Sulfonamides

Global Trachoma Treatment Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Topical

Global Trachoma Treatment Market Size by Age-group & CAGR (2025-2032)

  • Market Overview
  • Children
  • Adults
  • Geriatric

Global Trachoma Treatment Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

Global Trachoma Treatment Market Size & CAGR (2025-2032)

  • North America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • US
    • Canada
  • Europe (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Drug Class, Route of Administration, Age-group, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Private Limited (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bausch Health Companies Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations